Study of two drugs for newly diagnosed ph+ leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests two medicines together: olverembatinib (a pill) and blinatumomab (given by infusion). It is for people who are newly diagnosed with Ph+ ALL and have not had chemotherapy yet. The goal is to see if this combination works well and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must have newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)
- You must not have received any prior chemotherapy or targeted therapy (TKI pills) for this condition (except for pre-treatment preparation)
- You must be in reasonably good overall health (able to carry out daily activities)
- Your heart, liver, and kidney function must be within certain limits (checked by blood tests)
- You must not have HIV, active hepatitis B or C, uncontrolled infections, or other serious conditions (like severe bleeding or pancreatitis)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—olverembatinib, a bispecific T-cell engager, and chidamide—for adults newly diagnosed with Ph+ ALL who cannot have a stem cell transplant. The goal is to see if this treatment works well without needing intensive chemotherapy.
This trial tests a combination of three drugs (venetoclax, olverembatinib, and prednisone) for adults newly diagnosed with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL). The goal is to see if this combination is safe and effective.
This trial tests a sequence of three drugs for adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) that does not have the Philadelphia chromosome. The goal is to see if this approach can better treat the leukemia.
This trial tests two drugs—blinatumomab (an immune therapy) and olverembatinib (a targeted pill)—for people with a specific type of ALL that has the Ph chromosome or BCR::ABL1 gene. It aims to see if this combination works well in controlling the disease.
This trial tests a new targeted drug, olverembatinib, in adults newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if this drug can help control the leukemia with manageable side effects.
This trial tests a new treatment plan for children and teens newly diagnosed with a specific type of leukemia called Philadelphia chromosome-positive B-ALL. The goal is to see if the approach improves outcomes.
Hear when a new Philadelphia-Positive ALL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.